Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 10/20 | 1.00 |
| ▸ | FLT1 | P17948 | 9/20 | 1.00 |
| ▸ | FLT3 | P36888 | 9/20 | 1.00 |
| ▸ | CSF1R | P07333 | 8/20 | 1.00 |
| ▸ | LCK | P06239 | 8/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 6/20 | 1.00 |
| ▸ | AURKA | O14965 | 6/20 | 1.00 |
| ▸ | ABL1 | P00519 | 6/20 | 1.00 |
| ▸ | FYN | P06241 | 6/20 | 1.00 |
| ▸ | LYN | P07948 | 6/20 | 1.00 |
| ▸ | BLK | P51451 | 6/20 | 1.00 |
| ▸ | GSK3B | P49841 | 5/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 5/20 | 1.00 |
| ▸ | PLK4 | O00444 | 5/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 5/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 1.00 |
| ▸ | MARK3 | P27448 | 5/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 5/20 | 1.00 |
| ▸ | NEK2 | P51955 | 5/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30055372 | 1.00 | KIT (1.00) | KITFLT1FLT3CSF1RLCK | |
| Bromide SCHEMBL5436521 | 0.99 | KIT (0.98) | KITFLT1FLT3CSF1RLCK | |
| Hydrochloric Acid SCHEMBL4301600 | 0.99 | KIT (0.98) | KITFLT1FLT3CSF1RLCK | |
| Alcohol SCHEMBL3238965 | 0.97 | FLT1 (0.93) | KITFLT1FLT3CSF1RLCK | |
| SCHEMBL3567468 | 0.91 | KIT (0.83) | KITFLT1FLT3CSF1RLCK | |
| SCHEMBL4473254 | 0.91 | KIT (0.83) | KITFLT1FLT3CSF1RLCK | |
| SCHEMBL4487735 | 0.90 | KIT (0.82) | KITFLT1FLT3CSF1RLCK | |
| SCHEMBL4486498 | 0.90 | KIT (0.82) | KITFLT1FLT3CSF1RLCK | |
| SCHEMBL4478648 | 0.89 | FLT1 (0.79) | KITFLT1FLT3CSF1RLCK | |
| SCHEMBL4478281 | 0.88 | KIT (0.78) | KITFLT1FLT3CSF1RLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143459-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR | ABBOTT GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | claimed |
| US-20090270424-A1 | Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea hydrochloride | ABBOTT LABORATORIES | 2009-10-29 | — | — | US | claimed |
| EP-2089003-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR | Abbott GmbH & Co. KG (DE) | 2009-08-19 | — | — | EP | claimed |
| WO-2009100176-A2 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | WO | claimed |
| US-20090203709-A1 | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | claimed |
| WO-2008055966-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR | ABBOTT GMBH & CO. KG (DE) | 2008-05-15 | — | — | WO | claimed |
| US-20070161657-A1 | Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea hydrobromide | ABBOTT LABORATORIES | 2007-07-12 | — | — | US | claimed |
| US-20070161656-A1 | N-(4-(4-aminothieno[2,3-d]pyrimidin-5-YL)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea crystalline form 2 | ABBOTT LABORATORIES | 2007-07-12 | — | — | US | claimed |
| US-20070161660-A1 | Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea maleate | ABBOTT LABORATORIES | 2007-07-12 | — | — | US | claimed |
| US-20070161658-A1 | Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl) phenyl)urea camphorsulfonate | ABBOTT LABORATORIES | 2007-07-12 | — | — | US | claimed |
| US-20070161661-A1 | Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanesulfonate | ABBOTT LABORATORIES | 2007-07-12 | — | — | US | claimed |
| US-20070161659-A1 | enzyme inhibitor of protein tyrosine kinases; anticarcinogenic agent; treating autoimmune diseases, angiogenic diseases; salts of compounds with desired physical and mechanical properties, solubility, dissolution rate, hardness, compressibility and melting point | ABBVIE INC. | 2007-07-12 | — | — | US | claimed |
| US-20070155758-A1 | Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate | ABBVIE INC. | 2007-07-05 | — | — | US | claimed |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | MICHAELIDES MICHAEL R | 2006-12-07 | — | — | US | claimed |
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBVIE INC. | 2004-01-22 | — | — | US | claimed |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | claimed |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-09-25 | — | — | US | claimed |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-09-25 | — | — | US | disclosed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KIT 394/4885FLT1 337/4885FLT3 29/4885 |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | ABL1, LCK, ERBB2 | KIT 361/4885FLT1 459/4885FLT3 16/4885 |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KIT 394/4885FLT1 337/4885FLT3 29/4885 |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KIT 359/4885FLT1 357/4885FLT3 44/4885 |
| US-20090203709-A1 | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor | SRC, LYN, SYK | KIT 101/4885FLT1 121/4885FLT3 9/4885 |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | CHEK2, CILK1, DCK | KIT 1046/4885FLT1 3929/4885FLT3 527/4885 |
| US-20100143459-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR | SRC, LYN, SYK | KIT 101/4885FLT1 121/4885FLT3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.